The disparity in access to generic semaglutide, the active ingredient in Ozempic, between Canada and the United States has laid bare a fundamental dysfunction in American pharmaceutical pricing. While Canadian regulators this week approved the first generic version of the blockbuster diabetes drug, US patients face continued monopoly pricing that can exceed $1,000 per month without insurance.
The divergence stems from distinct regulatory and market structures. Canada's Patented Medicine Prices Review Board has long imposed price caps that keep branded drugs affordable. Once a patent expires, generic manufacturers can enter quickly, driving costs down further. In contrast, the United States lacks a centralised price negotiation mechanism. The Inflation Reduction Act of 2022 grants Medicare limited negotiation power, but the process is slow and excludes drugs like Ozempic until 2026.
Moreover, the US patent system allows manufacturers to file secondary patents on dosage forms, delivery devices, and manufacturing processes. Novo Nordisk, the Danish maker of Ozempic, holds patents that extend protection until at least 2032. Canadian courts have been more assertive in rejecting such secondary patents, allowing generics to launch sooner.
The result is a striking price gap. A month's supply of Ozempic in Canada costs roughly $300. In the United States, the list price is $950. Even after rebates and insurance negotiations, many patients face high out-of-pocket costs. The arrival of a Canadian generic will likely push prices below $200, widening the transatlantic chasm.
Health economists argue that the US system prioritises innovation incentives over affordability. But the human cost is rising. A recent CDC study found that one in five US adults with diabetes report rationing insulin or other glucose-lowering drugs due to cost. Ozempic, also used for weight loss, is increasingly sought after, but insurance coverage remains erratic.
Efforts to reform US pricing face stiff opposition from the pharmaceutical lobby. A 2023 Congressional Budget Office analysis estimated that allowing Medicare to negotiate prices for all drugs would save $500 billion over a decade. Yet legislation remains stalled. Meanwhile, Canada's move offers a natural experiment: if Canadians gain cheaper access to a drug that improves health outcomes, the pressure on Washington to act will intensify.
The geopolitical implications are not lost on policymakers. Canada's ability to deliver a generic Ozempic underscores the power of robust antitrust enforcement and price regulation. For the United States, the lesson is clear: without structural reform, the world's most expensive healthcare system will continue to fail its most vulnerable patients.
